Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues
- 30 April 2004
- journal article
- research article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 30 (2) , 165-172
- https://doi.org/10.1016/j.ctrv.2003.07.006
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2000
- Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.Journal of Clinical Oncology, 1996
- Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) AntibodyNew England Journal of Medicine, 1993
- Cancer mortality after iodine‐131 therapy for hyperthyroidismInternational Journal of Cancer, 1992
- Cancer Risk After Iodine-131 Therapy for HyperthyroidismJNCI Journal of the National Cancer Institute, 1991
- Treatment of Lymphoma With Radiolabeled Antibody: Elimination of Tumor Cells Lacking Target AntigenJNCI Journal of the National Cancer Institute, 1990
- Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.Journal of Clinical Oncology, 1985
- Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodiesMedical Physics, 1984
- Characterization of a human B lymphocyte-specific antigen.The Journal of Immunology, 1980